Smartphone maker HTC Corp (宏達電) has set its sights on earning an operating license from the Food and Drug Administration to commercialize a new medical virtual-reality (VR) product in the first quarter of next year.
Dubbed Surgical Theater, the VR product could begin to be adopted in clinical use and provide HTC with new revenue streams from the healthcare sector, the company said at a news conference yesterday.
The company also announced that it has sold Taipei Medical University its latest VR offering, 3D Organon, a bundle of 10 Vive Pro VR headsets that provide visualized anatomy information for education.
Photo by Kao Shih-ching, taipei Times
Medical students usually learn human anatomy from 2D models and diagrams in textbooks, or from donated cadavers, which are often in short supply, university Department of Anatomy professor Chang Hung-ming (張宏名) told the Taipei Times.
With the VR teaching system, students can see a computerized simulation that more clearly depicts human anatomy, especially the nervous system, whose components are thin and mostly hidden behind muscles and cavities, Chang said.
A 360o view allows users to see the human body from all angles to better understand how everything is connected, and they can also peel back layers or isolate 4,000 body parts to have a specific view, HTC healthcare division DeepQ director Jerry Cheng (鄭志偉) said.
“Users can even go through the virtual body to have a clear look inside at parts such as the spine and cavities,” he said.
However, it is hard for a VR system to substitute for “silent teachers” (大體老師) — people who have donated their bodies to medical schools — as “students cannot touch or feel the elasticity of muscles in virtual reality,” Chang said.
Besides Taipei Medical University, HTC has also sold 3D Organon to Tri-Service General Hospital and Taipei Municipal Wanfang Hospital, which plan to use the product for shared decisionmaking with patients, Cheng said.
While the firm has begun marketing 3D Organon, which costs about NT$100,000 per unit, HTC said it has also applied for a license for Surgical Theater, which would cost significantly more.
The company has received three medical appliance licenses from the US Food and Drug Administration for Surgical Theater, which provides accurate information that can even be used to help surgeons navigate operations, Cheng said.
As HTC has already conducted clinical trials in the US, it expects to receive approval from the Taiwanese agency by the first quarter of next year, Cheng said, adding that it would market the product to domestic hospitals first and expects to see revenue from the healthcare sector soar.
EXPANSION: The investment came as ASE in July told investors it would accelerate capacity growth to mitigate supply issues, and would boost spending by 16 percent ASE Technology Holding Co (ASE, 日月光投控), the world’s biggest chip assembly and testing service provider, yesterday said it is investing NT$17.6 billion (US$578.6 million) to build a new advanced chip packaging facility in Kaohsiung to cope with fast-growing demand from artificial intelligence (AI), high-performance-computing (HPC) and automotive applications. The new fab, called K18B, is to commence operation in the first quarter of 2028, offering chip-on-wafer-on-substrate (CoWoS) chip packaging and final testing services, ASE said in a statement. The fab is to create 2,000 new jobs upon its completion, ASE said. A wide spectrum of system-level chip packaging technologies would be available at
Taiwan’s foreign exchange reserves hit a record high at the end of last month, surpassing the US$600 billion mark for the first time, the central bank said yesterday. Last month, the country’s foreign exchange reserves rose US$5.51 billion from a month earlier to reach US$602.94 billion due to an increase in returns from the central bank’s portfolio management, the movement of other foreign currencies in the portfolio against the US dollar and the bank’s efforts to smooth the volatility of the New Taiwan dollar. Department of Foreign Exchange Director-General Eugene Tsai (蔡炯民)said a rate cut cycle launched by the US Federal Reserve
HEAVYWEIGHT: The TAIEX ended up 382.67 points, with about 280 of those points contributed by TSMC shares alone, which rose 2.56 percent to close at NT$1,400 Shares in Taiwan broke records at the end of yesterday’s session after contract chipmaker Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) hit a fresh closing-high amid enthusiasm toward artificial intelligence (AI) development, dealers said. The TAIEX ended up 382.67 points, or 1.45 percent, at the day’s high of 26,761.06. Turnover totaled NT$463.09 billion (US$15.22 billion). “The local main board has repeatedly hit new closing highs in the past few sessions as investors continued to embrace high hopes about AI applications, taking cues from a strong showing in shares of US-based AI chip designer Nvidia Corp,” Hua Nan Securities Co (華南永昌證券) analyst Kevin Su
Nvidia Corp’s major server production partner Hon Hai Precision Industry Co (鴻海精密) reported 10.99 percent year-on-year growth in quarterly sales, signaling healthy demand for artificial intelligence (AI) infrastructure. Revenue totaled NT$2.06 trillion (US$67.72 billion) in the last quarter, in line with analysts’ projections, a company statement said. On a quarterly basis, revenue was up 14.47 percent. Hon Hai’s businesses cover four primary product segments: cloud and networking, smart consumer electronics, computing, and components and other products. Last quarter, “cloud and networking products delivered strong growth, components and other products demonstrated significant growth, while smart consumer electronics and computing products slightly declined,” compared with the
RSS